2023
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction
Avula V, Sharma G, Kosiborod M, Vaduganathan M, Neilan T, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang E, Ky B, Lenihan D, Nohria A, Dani S, Ganatra S. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction. JACC Heart Failure 2023, 12: 67-78. PMID: 37897456, DOI: 10.1016/j.jchf.2023.08.026.Peer-Reviewed Original ResearchConceptsCancer therapy-related cardiac dysfunctionSGLT2 inhibitor useGuideline-directed medical therapyHeart failureInhibitor useSGLT2 inhibitorsMedical therapyCardiac dysfunctionAntineoplastic therapyAtrial fibrillation/flutterType 2 diabetes mellitusAcute HF exacerbationCox proportional HRsAcute kidney injuryRenal replacement therapyRetrospective cohort analysisIschemic heart diseaseRisk of cardiomyopathyAggregate patient dataTriNetX Research NetworkProportional HRsCause hospitalizationCause mortalityHF exacerbationKidney injury
2021
Outcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation
Guha A, Caraballo C, Jain P, Miller PE, Owusu‐Guha J, Clark KAA, Velazquez EJ, Ahmad T, Baldassarre LA, Addison D, Weintraub NL, Desai NR. Outcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation. ESC Heart Failure 2021, 8: 2866-2875. PMID: 33982867, PMCID: PMC8318466, DOI: 10.1002/ehf2.13362.Peer-Reviewed Original ResearchConceptsAnthracycline-induced cardiomyopathyIschemic cardiomyopathyCardiomyopathy patientsCF-LVADICM patientsLeft ventricular assist device implantationContinuous-flow LVAD implantationHigher major bleeding riskVentricular assist device implantationEnd-stage heart failureMechanically Assisted Circulatory SupportCox proportional hazards modelCF-LVAD implantationAcute kidney injuryMajor bleeding riskAssist device implantationEtiology of cardiomyopathyProportional hazards modelBleeding riskKidney injuryInteragency RegistryLVAD implantationMajor infectionMedian survivalRespiratory support
2019
Using FDG-PET to guide targeted cardiac magnetic resonance imaging in patients with suspected cardiac sarcoidosis
Sharp MB, Soufer A, Abdelmessih M, Rosenfeld LE, Baldassarre LA, Miller EJ. Using FDG-PET to guide targeted cardiac magnetic resonance imaging in patients with suspected cardiac sarcoidosis. Journal Of Nuclear Cardiology 2019, 27: 688-690. PMID: 30737635, DOI: 10.1007/s12350-019-01640-z.Peer-Reviewed Original Research
2016
Serial Native T1 Mapping to Monitor Cardiac Response to Treatment in Light-Chain Amyloidosis
Hur DJ, Dicks DL, Huber S, Mojibian HR, Meadows JL, Seropian SE, Baldassarre LA. Serial Native T1 Mapping to Monitor Cardiac Response to Treatment in Light-Chain Amyloidosis. Circulation Cardiovascular Imaging 2016, 9: e004770. PMID: 27682238, DOI: 10.1161/circimaging.116.004770.Peer-Reviewed Original Research